Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 bioavailability study of CTx-1302 (dextroamphetamine) in ADHD patients

Next Previous
Trial Profile

Phase 1/2 bioavailability study of CTx-1302 (dextroamphetamine) in ADHD patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions

Most Recent Events

  • 14 Aug 2024 According to a Cingulate Therapeutics media release, the company expects to start trial in mid-2024.
  • 13 Nov 2023 According to a Cingulate Therapeutics media release, the company expects to file IND in the first half of 2024.
  • 10 Mar 2023 According to a Cingulate Therapeutics media release, the company planned this study for mid-2024 and if the results from this study are successful, the company plans to begin pivotal phase 3 clinical trials in all patient segments for CTx-1302 in late 2024 or early 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top